Latest & greatest articles for fluoxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluoxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluoxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluoxetine

1. Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. (PubMed)

Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. BACKGROUND: Results of small trials indicate that fluoxetine might improve functional outcomes after stroke. The FOCUS trial aimed to provide a precise estimate of these effects. METHODS: FOCUS was a pragmatic, multicentre, parallel group, double-blind, randomised, placebo-controlled trial done at 103 hospitals in the UK. Patients were eligible if they were aged 18 (...) years or older, had a clinical stroke diagnosis, were enrolled and randomly assigned between 2 days and 15 days after onset, and had focal neurological deficits. Patients were randomly allocated fluoxetine 20 mg or matching placebo orally once daily for 6 months via a web-based system by use of a minimisation algorithm. The primary outcome was functional status, measured with the modified Rankin Scale (mRS), at 6 months. Patients, carers, health-care staff, and the trial team were masked

Full Text available with Trip Pro

2018 Lancet

2. Fluoxetine

Fluoxetine Top results for fluoxetine - Trip Database or use your Google+ account Turning Research Into Practice My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for fluoxetine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

2018 Trip Latest and Greatest

3. The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial

The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial 29783900 2018 05 22 1477-0873 2018 May 01 Clinical rehabilitation Clin Rehabil The efficacy comparison of citalopram, fluoxetine, and placebo on motor recovery after ischemic stroke: a double-blind placebo-controlled randomized controlled trial. 269215518777791 10.1177/0269215518777791 The present study aimed to assess (...) the effectiveness of oral citalopram, compared with fluoxetine and a placebo, in patients with post-stroke motor disabilities. A randomized double-blind placebo-controlled clinical trial was conducted between January 2015 and January 2016. The neurology department of a university-affiliated urban hospital in Tehran, Iran. Ninety adult patients with acute ischemic stroke, hemiplegia, or hemiparesis and a Fugl-Meyer Motor Scale score of below 55 were included. Participants were randomly allocated to one of three

2018 EvidenceUpdates

4. Effect of Fluoxetine Administration on Clinical and Echocardiographic Findings in Patients with Mitral Valve Prolapse and Generalized Anxiety Disorder: Randomized Clinical Trial. (PubMed)

Effect of Fluoxetine Administration on Clinical and Echocardiographic Findings in Patients with Mitral Valve Prolapse and Generalized Anxiety Disorder: Randomized Clinical Trial. 28243397 2017 02 28 2017 03 02 9 1 2017 Jan Electronic physician Electron Physician Effect of Fluoxetine Administration on Clinical and Echocardiographic Findings in Patients with Mitral Valve Prolapse and Generalized Anxiety Disorder: Randomized Clinical Trial. 3483-3491 10.19082/3483 Mitral valve prolapse (MVP) is (...) accompanied by mental disorders including anxiety, which has similar presentations as MVP. It is hypothesised that treatment of anxiety might reduce the symptoms of MVP. The aim of this study was to assess the clinical and echocardiographic effects of fluoxetine administration in patients with MVP and anxiety. This randomized clinical trial was conducted on patients with documented MVP and generalised anxiety disorder (GAD) who were referred to Mashhad University of Medical Sciences cardiology clinics

Full Text available with Trip Pro

2017 Electronic physician

5. Effectiveness of cognitive behavioral therapy and fluoxetine on sexual function of women with obsessive compulsive disorder: A double-blind randomized controlled trial. (PubMed)

Effectiveness of cognitive behavioral therapy and fluoxetine on sexual function of women with obsessive compulsive disorder: A double-blind randomized controlled trial. 28070247 2017 01 10 2017 02 24 8 11 2016 Nov Electronic physician Electron Physician Effectiveness of cognitive behavioral therapy and fluoxetine on sexual function of women with obsessive compulsive disorder: A double-blind randomized controlled trial. 3156-3163 10.19082/3156 Obsessive compulsive disorder (OCD) is a mental (...) health concern due to its various negative consequences, especially in sexual function. Therefore, the treatment of sexual dysfunction in women with OCD is important in order to improve the patient's marital function and mental health. To compare the sexual behavior and sexual and marital satisfaction in women with obsessive-compulsive disorder (OCD) before and after treatment with fluoxetine and cognitive behavior therapy. This randomized clinical trial was conducted at psychiatric and psychological

Full Text available with Trip Pro

2017 Electronic physician

6. Hypersexuality: fluoxetine

Hypersexuality: fluoxetine Hyperse Hypersexuality: fluo xuality: fluox xetine etine Evidence summary Published: 21 July 2015 nice.org.uk/guidance/esuom46 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in July 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up- to-date information. Summary No randomised controlled trials (RCTs) which evaluate the use (...) of fluoxetine in the treatment of hypersexuality were found, nor any studies that compared fluoxetine with any of the hormonal treatments licensed to treat hypersexuality. Limited evidence from 3 small, short-term observational studies suggests that fluoxetine may improve some measurements of hypersexuality and sexual preoccupation in men who have either been convicted of a sexual offence or who have a paraphilia or a non-paraphilic sexual addiction. However, these studies had a number of limitations which

2015 National Institute for Health and Clinical Excellence - Advice

7. Fluoxetine

Fluoxetine USE OF FLUOXETINE IN PREGNANCY 0344 892 0909 USE OF FLUOXETINE IN PREGNANCY (Date of issue: January 2017 , Version: 2.2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) used (...) in the treatment of depression, obsessive-compulsive disorder and bulimia nervosa. The majority of studies have demonstrated no statistically significant increase in overall risk of any malformation, with only one cohort study and two meta-analyses which combined the same primary data suggesting a slight increase in occurrence. Data concerning the risk of cardiac malformation following fluoxetine use in early pregnancy are conflicting, and whilst most studies have shown no association, three

2014 UK Teratology Information Service

8. Continuation-phase cognitive therapy and fluoxetine are effective in reducing the risk of relapse/recurrence in major depression after incomplete remission

Continuation-phase cognitive therapy and fluoxetine are effective in reducing the risk of relapse/recurrence in major depression after incomplete remission Continuation-phase cognitive therapy and fluoxetine are effective in reducing the risk of relapse/recurrence in major depression after incomplete remission | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Continuation-phase cognitive therapy and fluoxetine are effective in reducing the risk of relapse/recurrence in major depression after incomplete remission Article Text Psychological

2014 Evidence-Based Mental Health

9. Suicidal Thoughts and Behavior With Antidepressant Treatment: Reanalysis of the Randomized Placebo-Controlled Studies of Fluoxetine and Venlafaxine (PubMed)

Suicidal Thoughts and Behavior With Antidepressant Treatment: Reanalysis of the Randomized Placebo-Controlled Studies of Fluoxetine and Venlafaxine 22309973 2012 09 04 2012 09 17 2017 02 20 1538-3636 69 6 2012 Jun Archives of general psychiatry Arch. Gen. Psychiatry Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. 580-7 10.1001/archgenpsychiatry.2011.2048 The US Food and Drug Administration (...) issued a black box warning for antidepressants and suicidal thoughts and behavior in children and young adults. To determine the short-term safety of antidepressants by standard assessments of suicidal thoughts and behavior in youth, adult, and geriatric populations and the mediating effect of changes in depressive symptoms. All intent-to-treat person-level longitudinal data of major depressive disorder from 12 adult, 4 geriatric, and 4 youth randomized controlled trials of fluoxetine hydrochloride

Full Text available with Trip Pro

2012 EvidenceUpdates

10. Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression

Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression Article Text Aetiology Fluoxetine and sertraline may be associated with lower risk of suicide death than paroxetine in adults with depression

2012 Evidence-Based Mental Health

11. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial (PubMed)

Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial 21216670 2011 01 24 2011 03 01 2017 02 03 1474-4465 10 2 2011 Feb The Lancet. Neurology Lancet Neurol Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. 123-30 10.1016/S1474-4422(10)70314-8 Hemiplegia and hemiparesis are the most common deficits caused by stroke. A few small clinical trials suggest that fluoxetine enhances motor (...) recovery but its clinical efficacy is unknown. We therefore aimed to investigate whether fluoxetine would enhance motor recovery if given soon after an ischaemic stroke to patients who have motor deficits. In this double-blind, placebo-controlled trial, patients from nine stroke centres in France who had ischaemic stroke and hemiplegia or hemiparesis, had Fugl-Meyer motor scale (FMMS) scores of 55 or less, and were aged between 18 years and 85 years were eligible for inclusion. Patients were randomly

2011 EvidenceUpdates

12. Fluoxetine

Fluoxetine Drug Approval Package: Fluoxetine hydrochloride NDA #202133 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Fluoxetine 60 mg tablets Company: Edgemont Pharmaceuticals Application No.: 202133 Approval Date: 10/6/2011 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created: April 24, 2012 Vision impaired people

2011 FDA - Drug Approval Package

13. Fluoxetine, trazodone and ritanserin are more effective than placebo when used as add-on therapies for negative symptoms of schizophrenia

Fluoxetine, trazodone and ritanserin are more effective than placebo when used as add-on therapies for negative symptoms of schizophrenia Fluoxetine, trazodone and ritanserin are more effective than placebo when used as add-on therapies for negative symptoms of schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Fluoxetine, trazodone and ritanserin are more effective than placebo when used as add-on therapies for negative symptoms of schizophrenia Article Text Therapeutics Fluoxetine, trazodone and ritanserin are more effective than

2011 Evidence-Based Mental Health

14. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study (PubMed)

Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study 20360317 2010 07 02 2010 07 22 2016 12 15 1535-7228 167 7 2010 Jul The American journal of psychiatry Am J Psychiatry Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. 792-800 10.1176/appi.ajp.2009.09020284 The authors examined the safety (...) and efficacy of long-term fluoxetine monotherapy, lithium monotherapy, and placebo therapy in preventing relapse and recurrence of bipolar type II major depressive episode. The authors hypothesized that fluoxetine monotherapy would be superior to lithium monotherapy with a similar hypomanic mood conversion rate. Patients at least 18 years old who recovered from their major depressive episode during initial open-label fluoxetine monotherapy were randomly assigned to receive 50 weeks of double-blind

Full Text available with Trip Pro

2010 EvidenceUpdates

15. Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis (PubMed)

Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis 20653802 2010 07 26 2011 08 01 2013 11 21 1742-1241 64 9 2010 Aug International journal of clinical practice Int. J. Clin. Pract. Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis. 1310-7 10.1111/j.1742-1241.2010.02437.x Depression may affect patients' recovery and even their survival rate after stroke, but it is often overlooked or inadequately managed (...) ; data regarding the prophylactic efficacy and safety of fluoxetine are inconsistent in this setting. The objective of the study is to systematically assess the prophylactic efficacy and safety of fluoxetine for poststroke depression in patients with stroke. We searched electronic databases up to December 2009 for studies evaluating the prophylactic efficacy of fluoxetine in patients with stroke. The pooled odds ratio (OR), weighted mean difference (WMD), incremental efficiency and 95% confidence

Full Text available with Trip Pro

2010 EvidenceUpdates

16. Fluoxetine: possible small risk of congenital cardiac defects

Fluoxetine: possible small risk of congenital cardiac defects Fluoxetine: possible small risk of congenital cardiac defects Drug Safety Update - GOV.UK GOV.UK uses cookies to make the site simpler. Search Fluoxetine: possible small risk of congenital cardiac defects From: Published: 1 March 2010 Therapeutic area: and Recent epidemiological evidence suggests a possible small increased risk of congenital cardiac defects in association with fluoxetine in early pregnancy, similar to that seen (...) with paroxetine. There are insufficient data to draw conclusions on whether there is a similar risk for other SSRIs. The potential risks should be considered in the context of the benefits of treatment Article date: March 2010 Fluoxetine (brand leader Prozac) is a commonly used antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) class of medicines. Depressive symptoms and major depressive disorders occur in pregnant women with prevalence rates ranging from 7% to 20%. Untreated

2010 MHRA Drug Safety Update

17. Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis

Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis Fluoxetine for the prophylaxis of poststroke depression in patients with stroke: a meta-analysis Yi ZM, Liu F, Zhai SD CRD summary This review found that fluoxetine reduced incidence of newly diagnosed depression in patients with stroke, but did not reduce the symptom severity of post-stroke depression (...) . The authors’ conclusion on the benefits of fluoxetine is likely to be reliable, but the conclusion on symptom severity was influenced by extensive variation in the included trials. Authors' objectives To assess the prophylactic efficacy and safety of fluoxetine for post-stroke depression in patients with stroke. Searching Sixteen databases, including PubMed, EMBASE, the Cochrane Library and Chinese databases were searched up to December 2009 for relevant studies published in English or Chinese; search

Full Text available with Trip Pro

2010 DARE.

18. Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin

Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin Article Text Aetiology Current use of venlafaxine not associated

2010 Evidence-Based Mental Health

19. Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder

Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Compared with fluoxetine monotherapy, mirtazapine plus venlafaxine or fluoxetine increase remission but not response in patients with major depressive disorder Article Text

2010 Evidence-Based Mental Health

20. Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK

Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK Lenox-Smith A, Greenstreet L, Burslem K, Knight C Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of venlafaxine versus either generic fluoxetine or generic amitriptyline for the first-line treatment of patients with major depressive disorder. The authors concluded that, despite its relatively high

2009 NHS Economic Evaluation Database.